Chronic Spontaneous Urticaria Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Companies – Novartis, Genentech, Sanofi, Regeneron, Roche, and others

Chronic Spontaneous Urticaria Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Companies - Novartis, Genentech, Sanofi, Regeneron, Roche, and others

“Delveinsight Business Research LLP”
DelveInsight’s “Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Spontaneous Urticaria Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Chronic Spontaneous Urticaria market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Chronic Spontaneous Urticaria Market

Chronic Spontaneous Urticaria: An Overview

Chronic spontaneous urticaria (CSU) or Chronic Idiopathic urticaria (CIU) is defined as persistent symptoms of urticaria for 6 weeks or more. It is a distressing skin condition that causes red, swollen, itchy, and sometimes painful hives or “wheals” on the skin.

It is associated with autoimmunity in almost half of the cases, but the remaining cases still remain “idiopathic,” and all are considered spontaneous. Therefore, the term chronic spontaneous urticaria (CSU) has been employed to indicate chronic urticaria that is endogenous and independent of any external physical stimulus, which is conceptually helpful and does not imply knowing or not-knowing the cause.

Several drugs have been implicated in the treatment of chronic urticaria with evidence ranging from randomized, double-blind placebo-controlled clinical investigations to anecdotal case reports. The newest guidelines recommend a stepwise approach to the pharmacological treatment of chronic urticaria. 

Chronic Spontaneous Urticaria Market Key Facts

  • As per a study by T. Zuberbier et al. (2009), the lifetime prevalence for any subtype of urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria do not only cause a decrease in quality of life, but also affect performance at work and school and, as such, are members of the group of severe allergic diseases.

  • According to Maurer et al. (2019), two-thirds of the chronic urticaria cases were spontaneous.

  • According to Wertentail et al. (2019), female patients had a higher prevalence of CU across all age groups. Seventy-three percent (73%) of the total chronic urticaria patients were females as compared to 27% of male patients.

  • According to Balp et al. (2017), almost 50% of patients had moderate-to-severe disease activity as reported by Urticaria Activity Score.

Chronic Spontaneous Urticaria Market

The Chronic Spontaneous Urticaria Market is expected to grow in the coming years owing to the rising awareness about the indication, improved management, and better outcomes with the launch of the emerging therapies.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Chronic Spontaneous Urticaria market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Chronic Spontaneous Urticaria market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Chronic Spontaneous Urticaria Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Chronic Spontaneous Urticaria Epidemiology Segmentation

  • Total Prevalent cases 

  • Gender-Specific cases 

  • Age-specific cases

  • Total diagnosed and treatable prevalent cases

Chronic Spontaneous Urticaria Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Spontaneous Urticaria market or expected to get launched during the study period. The analysis covers Chronic Spontaneous Urticaria market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Spontaneous Urticaria Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report –

Chronic Spontaneous Urticaria Therapeutics Analysis

Some of the key companies in the Chronic Spontaneous Urticaria Market include:

  • Novartis

  • Genentech

  • Sanofi 

  • Regeneron

  • Roche

And many others

Chronic Spontaneous Urticaria Therapies covered in the report include:

  • Ligelizumab (LOU064)

  • Fenebrutinib

  • Dupilumab

And many more

Get More Detailed Insights Into the Emerging Therapies & Key Companies –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Chronic Spontaneous Urticaria Competitive Intelligence Analysis

4. Chronic Spontaneous Urticaria Market Overview at a Glance

5. Chronic Spontaneous Urticaria Disease Background and Overview

6. Chronic Spontaneous Urticaria Patient Journey

7. Chronic Spontaneous Urticaria Epidemiology and Patient Population

8. Chronic Spontaneous Urticaria Treatment Algorithm, Current Treatment, and Medical Practices

9. Chronic Spontaneous Urticaria Unmet Needs

10. Key Endpoints of Chronic Spontaneous Urticaria Treatment

11. Chronic Spontaneous Urticaria Marketed Products

12. Chronic Spontaneous Urticaria Emerging Therapies

13. Chronic Spontaneous Urticaria Seven Major Market Analysis

14. Attribute Analysis

15. Chronic Spontaneous Urticaria Market Outlook (7 major markets)

16. Chronic Spontaneous Urticaria Access and Reimbursement Overview

17. KOL Views on the Chronic Spontaneous Urticaria Market.

18. Chronic Spontaneous Urticaria Market Drivers

19. Chronic Spontaneous Urticaria Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Bronchial Neoplasm Market
“Bronchial Neoplasm Market” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Bronchial Neoplasm Market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States